Rifaat El-Mallakh, MD
Psychiatry · Louisville, KYNPI 1174595300
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,346,588 of the $1,616,226 with a category attached, or 83.3%. 24 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 47.1% of the total. Among psychiatry clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,766 payments — averaging $915.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$762K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$348K
- Johnson & Johnson$126K
- Vanda Pharmaceuticals Inc.$106K
- Axsome Therapeutics, Inc.$78K
- Indivior Inc.$51K
- plus $145K from 18 others
Across 89 payments — averaging $844.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sumitomo Pharma America, Inc.$46K
- Janssen Research & Development, LLC$20K
- F. Hoffmann-la Roche AG$6K
- Sunovion Pharmaceuticals Inc.$2K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
What the payments were for
- Consulting fees$113,2407%
- Speaking & faculty fees$1,346,58883%
- Travel & lodging$121,5818%
- Food & beverage$34,5892%
- Education$2280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 823 | $761,996 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 325 | $348,209 |
| Johnson & Johnson | 158 | $125,956 |
| Vanda Pharmaceuticals Inc. | 103 | $106,375 |
| Axsome Therapeutics, Inc. | 54 | $77,974 |
| Indivior Inc. | 99 | $50,941 |
| Alkermes, Inc. | 38 | $41,513 |
| Teva Pharmaceuticals USA, Inc. | 32 | $27,096 |
| Eisai Inc. | 15 | $13,900 |
| Idorsia Pharmaceuticals US Inc | 19 | $12,885 |
| Neurocrine Biosciences, Inc. | 26 | $12,857 |
| AbbVie(2 entities) | 21 | $9,742 |
| Noven Pharmaceuticals, Inc. | 9 | $9,028 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 11 | $8,165 |
| E.r. Squibb & Sons, L.L.C. | 9 | $3,770 |
| Biogen | 2 | $3,198 |
| Sunovion Pharmaceuticals Inc. | 6 | $1,449 |
| Lundbeck LLC | 5 | $312 |
| Bioxcel Therapeutics, Inc. | 3 | $289 |
| Sage Therapeutics, LLC | 2 | $188 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $112 |
| Janssen Scientific Affairs, LLC | 2 | $99 |
| Novo Nordisk | 1 | $86 |
| Boehringer Ingelheim | 1 | $85 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$392,787
- REXULTI$360,663
- CAPLYTA$343,871
- ABILIFY ASIMTUFII$211,305
- ARISTADA$161,346
- SPRAVATO$123,812
- Fanapt$105,109
- Auvelity$76,878
- PERSERIS$49,866
- ARISTADA INITIO$40,336
- Dayvigo$13,820
- QUVIVIQ$12,471
- Austedo XR$10,542
- UZEDY$10,404
- VRAYLAR$9,135
- SECUADO$9,028
- INGREZZA$8,682
- AUSTEDO$5,270
- LATUDA$1,251
- LYBALVI$866
How this compares
$1,616,226 in reported general payments places this provider in the 95th percentile of 348 psychiatry providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 26 | $42,429 |
| NuedextaDextromethorphan Hbr/Quinidine | 18 | $26,904 |
| TrintellixVortioxetine Hydrobromide | 15 | $22,191 |
| Asenapine Maleate | 48 | $17,584 |
| AuvelityDextromethorphan Hbr/Bupropion | 22 | $16,173 |
| VraylarCariprazine Hcl | 15 | $15,204 |
| OzempicSemaglutide | 11 | $12,093 |
| BelsomraSuvorexant | 23 | $9,713 |
| Clozapine | 82 | $9,240 |
| Modafinil | 54 | $3,686 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 25 | $2,841 |
| Quetiapine Fumarate | 74 | $2,547 |
| Divalproex Sodium ErDivalproex Sodium | 35 | $2,309 |
| Atomoxetine Hcl | 20 | $2,290 |
| Bupropion XlBupropion Hcl | 49 | $2,188 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $348,209 | $42,42926 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $112 | $22,19115 claims |
| Axsome Therapeutics, Inc.Auvelity | $77,974 | $16,17322 claims |
| AbbVieVraylar | $9,742 | $15,20415 claims |
| Novo NordiskOzempic | $86 | $12,09311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 348 psychiatry providers in Kentucky.
Other psychiatry in Louisville
- Robert StewartLouisville$651K
- Ali FarooquiLouisville$393K
- Stephanie HallLouisville$106K
- Kelly ClarkLouisville$14K
- Michael HarrisLouisville$13K
- Yelena VaninaLouisville$12K
- Mohamed KhodeirLouisville$9K
- Kevin BaysLouisville$9K
- Terry HaganLouisville$8K
- Ronald McGavicLouisville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.